Deep COVID DeteCT: an international experience on COVID-19 lung detection and prognosis using chest CT by Lee, E.H. et al.
ARTICLE OPEN
Deep COVID DeteCT: an international experience on
COVID-19 lung detection and prognosis using chest CT
Edward H. Lee 1✉, Jimmy Zheng 1, Errol Colak 2, Maryam Mohammadzadeh3, Golnaz Houshmand 4, Nicholas Bevins5,
Felipe Kitamura 6, Emre Altinmakas7, Eduardo Pontes Reis8, Jae-Kwang Kim 9, Chad Klochko 4, Michelle Han 1,
Sadegh Moradian10, Ali Mohammadzadeh4, Hashem Sharifian3, Hassan Hashemi11, Kavous Firouznia 11, Hossien Ghanaati11,
Masoumeh Gity11, Hakan Doğan 7, Hojjat Salehinejad2, Henrique Alves 6, Jayne Seekins1, Nitamar Abdala 6, Çetin Atasoy7,
Hamidreza Pouraliakbar4, Majid Maleki4, S. Simon Wong12 and Kristen W. Yeom 1✉
The Coronavirus disease 2019 (COVID-19) presents open questions in how we clinically diagnose and assess disease course.
Recently, chest computed tomography (CT) has shown utility for COVID-19 diagnosis. In this study, we developed Deep COVID
DeteCT (DCD), a deep learning convolutional neural network (CNN) that uses the entire chest CT volume to automatically predict
COVID-19 (COVID+) from non-COVID-19 (COVID−) pneumonia and normal controls. We discuss training strategies and differences
in performance across 13 international institutions and 8 countries. The inclusion of non-China sites in training significantly
improved classification performance with area under the curve (AUCs) and accuracies above 0.8 on most test sites. Furthermore,
using available follow-up scans, we investigate methods to track patient disease course and predict prognosis.
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INTRODUCTION
Coronavirus disease 2019 (COVID-19) caused by severe acute
respiratory syndrome corona virus 2 (SAR-Cov-2) has inflicted a
global health crisis and was declared a pandemic in March 20201.
The high transmission rates that can lead to respiratory distress
and multiple organ failures, requisite critical care resources, and
rising mortality2–4 have prompted an urgent need for early
detection, accurate diagnosis, and predictive tools.
Real-time reverse-transcription polymerase chain reaction (RT-
PCR) is the primary method for SAR-Cov-2 diagnosis. However, RT-
PCR has shown variable sensitivity and specificity5–7 either due to
insufficient viral load, sample collection methods, or lack of
definitive reference standards8,9. Studies have reported character-
istic imaging features of COVID-19 pneumonia10 and proposed
chest CT to either complement RT-PCR or serve as the initial
workup in highly suspected cases given the potential for false
negative RT-PCR11–13 and to gauge disease severity14,15.
As the pandemic expands to global regions with limited access
to nucleic acid detection kits, chest CT may play a greater
diagnostic role for COVID-19 and disease monitoring, highlighting
a need for automated or quantitative analytics. Recently, studies
have reported success in deep learning methods with CT slices as
inputs for COVID-19 classification16–18 or segmentation outputs to
quantitate lung opacification and correlate disease severity19.
Machine learning can capitalize on large-scale, high-dimensional
image data and offers the opportunity to optimize a framework
for COVID-19 evaluation, including prognostic models that stratify
risk groups. This study goal was to develop Deep COVID DeteCT or
DCD, a 27-layer 3D model, which (1) classifies COVID-19
pneumonia (COVID+) from non-COVID-19 (COVID−) pneumonia
and normal lung, and (2) predicts disease course using chest CT.
To the best of our knowledge, our study investigates one of the
largest and most diverse patient population, and compares and
discusses differences in performance across 13 international sites.
The study sites are shown in Figs. 1, 2. Patient characteristics for
each site is shown in Fig. 2.
● We designed a simple-to-use model (DCD) for classification
trained and evaluated across 13 diverse sites from around
the world.
● We investigate generalizability across all 13 sites, and discuss
the contribution of participants outside of China on model
performance.
● We track the disease course of COVID+ confirmed patients by
using DCD features over time.
RESULTS
A deep 3D model for classification using 13 international
institutions
In task 1, we report high accuracies and Area under the Curve
(AUC) in Table 1 with Receiver Operating Characteristics (ROC)
curves shown in Fig. 3. Table 1 shows multiple training, validation,
and test configurations. For example, with test site ID 9, the model
is trained for 20 epochs and internally validated on all sites except
Henry Ford, GUMS, and TUMS-2. After validation, the model is
evaluated on the hold-out test site, Henry Ford. Our volumetric-
based approach is also far superior to a 2D approach using a
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ResNet-50 pretrained on ImageNet, which yielded accuracies that
were consistently lower. We also test the robustness of our models
across variations of CT image windows for bone, soft tissue, and
lung by changing pixel value thresholds during test-time. We
evaluate DCD with variations in pixel threshold values in order to
simulate the effect of sampling CT images at slightly different
windows. In our ROC curves (Fig. 3), we plot the individual ROC
curves and an averaged ROC curve with ±1 std. deviation error.
This experiment is necessary to ensure that our model perfor-
mance is robust and reproducible across a large diversity of scans.
We ensured that slight variations in the window parameter leads
to only modest and graceful degradation in ROC performance.
We investigate the contribution of non-China participants on
performance. We train DCD on sites 0 and 1 only and test on non-
China sites; we compare this strategy to one where we train DCD
on all non-China sites. The results are shown in Table 2. We show
that while AUCs were still very high except for two COVID− PNA
AUCs, for most of the sites, the AUCs were significantly higher for
the strategy that incorporated data from sites 2 to 11. ROC curves
for these are shown in Supplementary Fig. 2. Furthermore, we
Fig. 1 Institutions used in our study. Our AI model (DCD) captures the diversity of patients, labels, and scanners from around the world.
Permission was sought and granted by all relevant institutions to use their logos.
Fig. 2 Characteristics of patients by institution and country. This table summarizes the patient demographics used in our study.
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investigate the effect of fine-tuning by (1) training a model on a
set of sites, and (2) fine-tuning the model on a small subset of
patients from the test site of interest. For example, we train DCD
on sites 1 to 11 and fine-tune and internally validate for a
maximum of 20 epochs on 20% of China-1 patients. The test
accuracy on the remaining 80% of China-1 is 91.2%, whereas it is
71.6% without fine-tuning (70.7% on all China-1). Similarly, we
train on sites 0 to 10 and fine-tune on 20% of MosMedData. Fine-
tuning boosts performance from 73.2% to 80.6%. This is likely
because the model learned to capture large variations in
demographic and data collection practices. For example,
COVID+ cases from Einstein site were of mild severity while
those of TUMS-2 were severe; in fact, one-third of TUMS-2
COVID+ patients died. To illustrate this, we plot histograms of
predictions for all COVID+ cases for Einstein (Fig. 4), GUMS (Fig. 5),
and TUMS-2 (Fig. 6). COVID+ predictions from Einstein have lower
confidence and higher variability than those of GUMS and TUMS-
2. Next, we plot DCD features using t-distributed stochastic
neighbor embedding (TSNE) (Fig. 7) to provide intuition of how
the diagnosis predictions are arranged in a high-dimensional
space. Finally, we used DCD to generate gradient-based heat
maps20 (also known as Grad-CAM) on our external cohorts. In
Fig. 8, we illustrate examples of where the DCD features activate
strongly to key regions in the lungs. For example, in the COVID+
patients, we see almost all the ground glass opacity lighting up. In
COVID− patients, COVID+ activation is limited. A 3D view of our
model’s heatmap on a COVID+ patient is shown in Fig. 9.
A method to describe disease trajectory and prognosis using
learned features
In task 2, we deployed DCD on successive follow-up scans to
measure DCD features over time. The goal was to track the
progression of each patient’s individual disease status in an
unsupervised manner. Higher feature scores for a given scan
mean that the scan appears more similar to COVID+ population.
In Fig. 10, we compute features denoted as s(t) for follow-up
patients.
We show in Fig. 10(a) that many of the patients’ scores
increased rapidly to a peak within 10 days. This was then followed
by a gradual decline in COVID+ severity, which may indicate
patient recovery. Even at and beyond the end of their
hospitalization stay, many of the survivors’ lungs still contained
features characteristic of COVID+ active disease. We theorize that
we can use these features that map COVID+ severity over time to
predict prognosis.
We quantify prognosis by the length of hospitalization (in days)
measured from when the scan was imaged to time at discharge. A
longer hospitalization window is indicative of worse prognosis.
From our findings in Fig. 10, we expect that a large increase in
DCD features over a short time window between 2 scans is
indicative of a long hospitalization period and “high-risk”
prognosis outcome. Similarly, a significant decrease in features
over a short time indicates a low-risk prognosis. Features that
grow in time but flatten out may also indicate low-risk.
Furthermore, predicting prognosis is difficult with one scan alone,
and knowing two scans may not be enough to tell when the
patient’s feature score will peak. Two of these scenarios are shown
in the Supplementary Fig. 3. Our intuition tells us that models
trained to predict prognosis on hospitalization times can do better
by looking at many sequential scans than just one scan alone. In
the following experiments, we compared the prognostic perfor-
mance of two scans (one prior and one follow-up) to one
scan alone.
In Fig. 11 Kaplan–Meier (KM) are plotted on validation sets for
different model configurations. The models stratify the patients
into one of two groups: high-risk or low-risk. The first model (a)
uses 2 sequential scans (one prior and one follow-up study) as
inputs, while the second model (b) uses only one scan. We achieve
greater separation using two sequential scans (log-rank P= 5.3 ×
10−5). We achieve poor separation for a model trained using only
age and sex as inputs (c). As an extension of (a), we perform 5-fold
cross-validation and aggregate all 5 validation fold predictions in
one KM plot. Finally, in order to account for any human-bias
between discharge time and length of time between scans, we
train a model using only the length of time as input (i.e., no
images). This yields poor separation with P= 0.27.
To qualitatively assess the disease course of follow-up scans, we
present heat maps that attend to regions in three dimensions in
space and one in time. The Grad CAM20 of a 2D image, H(x, y),
reveal pixels that activate strongly to the predicted class. H(x, y) is
normalized throughout the entire (x, y)-plane from 0 to 1 for all
pixel values (x, y). In our work, because we aim to track the disease
trajectory from one scan to the next, we choose not to normalize
with respect to one scan alone. Instead, we multiply the gradient
maps by the feature score computed in Fig. 10. We compute a
new map, H(x, y, z, t), across both space and time. This does two
Table 1. Performance on all test sites.
Test site ID Institution Train/Val. sites Normals AUC COVID− PNA AUC COVID+ AUC Accuracy
0 China-1 1,..,11 0.948 0.741 0.858 0.707
1 China-2 0,2,...,11 0.988 0.80 0.908 0.789
2 Kyungpook 0,1,3,..,11 N/A N/A N/A 0.921
3 Stanford 0,..,2,4,..,11 0.952 0.831 0.93 0.804
4 Unity Health 0,..,3,5,..,11 0.98 0.829 0.914 0.775
5 Koç 0,..,4,6,..,11 0.948 0.776 0.909 0.779
6 Rajaie 0,..,5,7,..,11 0.984 0.811 0.858 0.767
7 Einstein 0,..,6,8,..,11 N/A N/A N/A 0.915
8 UNIFESP 0,..,7,9,..,11 0.987 0.895 0.916 0.828
9 Henry Ford 0,..,8,10,..,11 0.986 0.830 0.889 0.76
10 TUMS-1 0,..,9,11 0.978 N/A 0.933 0.881
11 MosMedData 0,..,10 0.806 N/A 0.808 0.747
12 GUMS 0,..,11 N/A N/A N/A 0.944
13 TUMS-2 0,..,11 N/A N/A N/A 0.974
Entries with N/A are due to class imbalance.
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Fig. 3 Receiver operating characteristics (ROC) curves and area under the curve (AUC) for different external test sites. The sites are: China-
1 (a), China-2 (b), Stanford (c), Unity Health (d), Koç (e), Rajaie (f), UNIFESP (g), Henry Ford (h), TUMS-1 (i), MosMedData (j). ROC curves were not
plotted for sites with imbalanced data: Kyungpook, GUMS, and TUMS-2. The confusion matrix for our model trained on all sites and finetuned
on 20% of site China-1 (15% train, 5% validation) and evaluated on the remaining 80% of China-1 (k).
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things: (1) scales the scan’s attention map by the degree of COVID
severity at time t relative to all time points, and (2) provides
direction information for when the CT becomes less similar to
COVID+ data distribution. In Fig. 12, we plot H(x, y, z, t) on a 24
year old patient who had 5 scans in the course of 50 days. On day
13, the patient was discharged. The feature score s(t= 12) at day
12’s scan is almost 0, which is why H(x, y, z, t= 12) ≈ 0.
DISCUSSION
To the best of our knowledge, our study investigates one of the
largest and most diverse patient population confirmed to have
Table 2. Performance of model trained on sites 0 and 1 versus a model trained on all sites.
Test Site Institution Train/Val. Sites Normals AUC COVID− PNA AUC COVID+ AUC
3 Stanford 0,1 0.898 0.741 0.906
3 Stanford 0,..,2,4,..,11 0.952 0.831 0.93
4 Unity Health 0,1 0.844 0.603 0.859
4 Unity Health 0,..,3,5,..,11 0.98 0.829 0.914
5 Koç 0,1 0.875 0.351 0.822
5 Koç 0,..,4,6,..,11 0.948 0.776 0.909
6 Rajaie 0,1 0.903 0.775 0.724
6 Rajaie 0,..,5,7,..,11 0.984 0.811 0.858
8 UNIFESP 0,1 0.929 0.347 0.928
8 UNIFESP 0,..,7,9,..,11 0.987 0.895 0.916
9 Henry Ford 0,1 0.967 0.620 0.874
9 Henry Ford 0,..,8,10,..,11 0.986 0.830 0.889
10 TUMS-1 0,1 0.948 N/A 0.947
10 TUMS-1 0,..,9,11 0.978 N/A 0.933
11 MosMedData 0,1 0.636 N/A 0.604
11 MosMedData 0,..,10 0.806 N/A 0.808
Fig. 4 DCD predictions for Site 7. Histogram of model outputs on
external hold-out test site 7 (Einstein) with only COVID+ cases.
Fig. 5 DCD predictions for Site 12. Histogram of model outputs on
external hold-out test site 12 (GUMS) with only COVID+ cases.
Fig. 6 DCD predictions for Site 13. Histogram of model outputs on
external hold-out test site 13 (TUMS-2) with only COVID+ cases.
Fig. 7 Two-dimensional manifold of features generated using
t-distributed stochastic neighbor embedding (TSNE) on the DCD
model. DCD evaluated on the test set of China-1 (80% of China-1). It
was trained on sites 1 to 11 and finetuned on the training set of
China-1 (20% of China-1).
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COVID-19 by RT-PCR tests and include 8 countries (Iran, Turkey,
China, South Korea, USA, Canada, Brazil, Russia) with diverse
geographic, genetic, racial, and ethnic backgrounds. We also
include urban (e.g., Detroit) and nonurban (e.g., Palo Alto) centers.
Some hospitals are specialty clinics, such as Rajaie Cardiovascular
Institute in Iran, where majority are cardiac patients with clinical
symptoms that mimic COVID-19 (e.g., shortness of breath) or have
high-risk factors with a lower threshold for COVID-19 workup or CT
screening, while others represent referral centers that treat
complex medical conditions, or a combination of outpatients
and inpatients (e.g., Unity Health-Toronto) admitted directly from
active COVID assessment centers. Our image dataset is also
diverse, acquired from multiple vendors (e.g., NeuViz, Siemens, GE,
Philips, Toshiba) and with heterogeneous imaging protocols, that
include contrast and non-contrast scans.
While many published AI works describe model performance,
many models are learned on homogeneous data sources and thus
raise questions of robustness and generalizability. Recognizing
such general limitation, one recent study18 report model
performance on COVID-19 data from China, Japan, and Italy.
While the results are promising with high prediction accuracy
(except for low accuracy in one Milan cohort), their controls
consisted entirely of patients from the United States, which could
raise concerns of bias. Notably, in our study, we find that contrast-
enhanced CT is used widely in North America (California,
Michigan, Toronto), whereas other international centers predomi-
nantly do not use contrast. This might reflect differences in clinical
practice, where a CT may serve as a screening/diagnostic tool for
COVID-19 (noncontrast CT) versus CT use to either problem-solve
or evaluate other diseases (e.g., pulmonary embolism) associated
with COVID-19. Using 13 international cohorts, we report high and
robust accuracies and AUCs across all external test sites in Table 1.
Unlike prior published AI works that combine lung segmenta-
tion and predictions17,18,21–23, we report use of a simple 3D model
that uses whole CT chest that might facilitate clinical translation.
Furthermore, while prior studies use human visual inspection 23,
software-based segmentation for scoring disease severity22,24,25,
we leverage learned features to conduct both supervised and
unsupervised learning. Prior chest CT studies have shown
characteristic COVID+ patterns, such as peripheral ground glass
opacities that are often bilateral, peripheral with contiguous and
multi-lobar extensions depending on disease severity26–28. COVID
+ can also be present with dynamic features that might reflect
disease evolution over time and recovery19,29,30. COVID+ features
can overlap with those of other infections, inhalation injury, or
drug toxicities. Figure 13 illustrates potential challenges in
differentiating COVID+ versus COVID− pneumonia. Furthermore,
many AI papers in COVID+ pneumonia detection have used either
individual 2D slices or combined 2D CNN features to form 2.5D
models16,31–33. One drawback is that using a 2D-only representa-
tion, such models could distort locality information in the sagittal
direction.
Further, we show that DCD could identify features relevant to
clinical outcome. We observe a distinct curve of features over time
that is characteristic among almost all follow-ups (Fig. 10). We
then apply supervision by fine-tuning DCD on hospitalization
times. In this experiment, we show KM curves of two predicted
populations deemed as high-risk or low-risk with hospitalization
rates. Separation was largest in our model when presented with
paired, temporally adjacent scans as opposed to one scan alone.
There are some limitations to our study. First, larger sample size
is always desirable. Nevertheless, we demonstrate model general-
izability in 13 sites and RT-PCR-positive 3529 unique patients
affected with COVID-19. Creating any prognostic model has
Fig. 8 Grad-CAM over CT scans of COVID19+ and COVID19- pneumonia patients. On top right, DCD correctly diagnosed the scan of a
COVID19- patient with PNA who showed signs of ground glass opacity.
Fig. 9 3D view of a model-generated 3D Grad-CAM superimposed
on the CT of a COVID+ case with bilateral peripheral ground glass
opacities and consolidation. The map was generated from only 1
forward and 1 backward pass of 1 example in the test set.
E.H. Lee et al.
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inherent challenges such as the existence of many complex
clinical variables. We do not examine the effects of different
therapies, which is beyond the scope of this study.
In conclusion, we present DCD, a single 3D model that
diagnoses and tracks disease course over hospitalization without
the aid of complex preprocessing. We leverage transfer learning
from Kinetics video dataset for classification; we show robust
generalizability across diverse international cohorts. We show
indicative patterns in DCD features that correlate with the patient
outcome. Finally, we show heat maps that highlight the visual
progression of a patient’s disease trajectory over time.
METHODS
Multi-center dataset
We conducted a multi-center retrospective study across 13 institutions
including 2 COVID+ datasets from China17 and 1 from Russia34.
Institutional review board (IRB) at participating hospitals approved this
retrospective study with waiver of consent. Waiver of consent was
granted by the IRB for the following reasons: (1) The research involves no
more than minimal risk to the participants because it involves materials
(data, documents, records) that have been or will be collected, and
precautions will be taken to ensure that confidentiality is maintained, (2)
the waiver will not adversely affect the rights and welfare of the
participants because procedures are in place to protect confidentiality,
and (3) information learned during the study will not affect the
treatment of participants. Patient demographics are summarized in
Fig. 2. The following represents the inclusion criteria: patients presented
with clinical symptoms suspicious for COVID-19 pneumonia, obtained at
least one confirmatory real time RT-PCR tests to determine COVID-19
status, and obtained diagnostic quality chest CT. For RT-PCR testing,
samples of respiratory secretions from bronchoalveolar lavage, endo-
tracheal aspirate, nasopharyngeal or oropharyngeal swabs were used.
Scanner models and slice thicknesses for participating institutions are
shown in Supplementary Fig. 1.
Image preprocessing
All raw data from institutions except for China-1 and MosMedData were
provided in Digital Imaging and Communications in Medicine (DICOM)
format. The majority of the patient DICOMs contained dynamic range of
pixel intensities consistent with that of a lung window. Patient DICOM
series were collected and scaled to 256 × 256 pixels. DCD was designed to
sample 24 planes evenly across the lung. To accommodate a large range of
slice thickness (1 to 5-mm), DCD uniformly sub-samples across the sagittal
plane until 24 approximately-equidistant slices are extracted per patient.
For data augmentation during training, we also generate additional 24-
plane samples by applying random jitter in the depth dimension. Finally,
before each 24 × 256 × 256 image is fed into the model for training, we
apply a clipping function that truncates all Hounsfield unit intensity values
above a fixed pre-determined value. This was to ensure that large
Hounsfield Unit values outside the lung (e.g., bone) does not saturate and
overwhelm the signal from the lung. During training, we randomly
cropped images to 240 × 240 and resized them back to 256 × 256,
performed random flipping in the x and y directions, and applied random
jitter in the depth dimension. During test-time, we measure ROC curves
and AUCs across different clipping values (±6.25% jitter) to simulate the
effect of sampling CT images at slightly different windows.
Fig. 10 Features from DCD for the follow-up patients over time. Scans with high scores indicate high similarity to the COVID+ PNA
population. Many patients show a representative feature trajectory with increasing COVID+ PNA intensity peaking near the time of discharge
followed by a subsequent decrease after discharge. a Time-series of COVID-19 survivors with 2 or more follow-up scans, and (b) 3D plot of
selected survivor scores that reveal similar trajectories.
E.H. Lee et al.
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DCD model training and evaluation
The DCD model consists of a 27-layer I3D-Inception feature extractor, 3D
spatial average pooling, and 1 fully-connected layer. The Inception
model35 was pretrained on Kinetics-600, a video dataset36.
In task 1, we designate one institution as the external hold-out test set
while pooling (merging) the others into the training and and internal
validation sets. The internal validation set is generated by randomly
sampling 5% of the pooled data without replacement. Training consisted
of minimizing cross-entropy loss with dropout and Adam optimization37
for 20 epochs. We evaluate on the internal validation set at every fifth of an
epoch. After training, we select the trained weights that maximizes the
validation accuracy to be used for evaluation on the test site. Future
improvements such as stratified sampling and selection of models that
maximizes the worst-case performance over all sites are topics of future
research. In Table 1, we illustrate the performance on all test sites.
In classifiers trained under cross-entropy loss, the output is a set of
prediction probabilities that correlate towards COVID disease severity. In
task 2, we use the (pre-activation) logit, denoted as s throughout this
paper, as the feature we use to track disease course. This feature can be
interpreted as follows: if the feature score of a patient is s(t= 0) > 0 and,
ds
dt > 0, the sequence of scans is transforming to be more COVID-like; if
ds
dt < 0, it suggests that this patient is recovering. Using these features, we
fine-tuned DCD, which was trained on sites 1 and 2 in classification task 1,
to predict patient prognosis on follow-up scans. Due to the limited number
of follow-ups, we split the scans on a per-patient basis into either training
or validation sets; we also perform an additional 5-fold cross-validation
procedure and aggregate predictions from each of the 5 validation folds. In
order to predict prognosis using two consecutive scans, the DCD’s
convolutional model backbone computed features for scans 1 and 2, and
concatenated features were passed through two fully-connected layers. On
the other hand, a model predicting prognosis using a single scan alone
uses only the convolutional backbone and two fully-connected layers
without concatenation. We quantify prognosis by the length of
hospitalization time (in days) measured from when the scan was imaged
to time at discharge. A longer hospitalization time is indicative of worse
prognosis. Rather than predicting the time using regression, we treat this
problem as a binary classification problem to classify whether the patient
will stay hospitalized for longer than 7 days (median) given the presenting
scan at any given time of the patient’s disease course. We define 7 days or
longer to indicate a subjective “high-risk” prognosis and below 7 days to
indicate a “low-risk” status. We perform classification instead of regression
to respect the fact that hospitalization times are inherently noisy. For
instance, a model learning to achieve 0 root-mean-square error on patients
whose discharge was delayed by non-medical reasons is counterproduc-
tive. Our model uses binary cross-entropy loss instead of Cox proportional-
hazards loss38 since (1) we designed this task as a classification problem to
compare and interpret easily to radiologists and (2) asking radiologists to
predict the number of days is not common clinical practice.
Fig. 11 Kaplan–Meier plots on COVID disease course. Different configurations of DCD: (a) 1 prior +1 follow-up scans, (b) 1 scan only, (c) age
and sex only, (d) 1 prior +1 follow-up scans (combines 5 validation folds in a 5-fold cross-validation experiment).
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8
npj Digital Medicine (2021)    11 Published in partnership with Seoul National University Bundang Hospital
Fig. 12 Case study using DCD on a follow-up patient (24 years old) with 5 scans. This patient was discharged on day 13. Modified
gradient heat maps, H(x, y, z, t) for all pixel coordinates (x, y, z), are superimposed onto the original CT, and color-coded (red for H(x, y, z) > 0
and blue for H(x, y, z) < 0). The model was originally trained on task 1 and evaluated on these unseen examples. Severity predicted by DCD
was highest on day 7 (as indicated by the visual difference between H on day 7 and day 1). On day 12, DCD’s H(x, y, z, t= 12) ≈ 0 indicates
significant recovery.
Fig. 13 Examples of COVID− PNA patients in our study that show heterogeneous features, some that are similar to COVID+ PNA. For
example, two COVID− patients with influenza PNA (red arrows), including H1N1 (long red arrow), show peripheral ground glass opacities
similar to COVID+.
E.H. Lee et al.
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Reporting summary
Further information on research design is available in the Nature Research
Reporting Summary linked to this article.
DATA AVAILABILITY
Not all the datasets generated and analyzed during the study are currently publicly
available. Datasets from Stanford, Koç, Unity Health, and UNIFESP have been
submitted to the Radiological Society North America for public release: RSNA
International COVID-19 Open Radiology Database (RICORD)39, and will be publicly
available in the near future.
CODE AVAILABILITY
We plan to open-source code at a future date with incremental public updates as we
obtain more results and data. Please check in https://github.com/edhlee/Deep-
COVID-DeteCT for updates.
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